Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 04-Apr-24 6:13 PM View:  | Miller Aine SVP, Dev & Head of IRE Office | Theravance Biopharma, Inc. (TBPH) | 02-Apr-24 | Grant | 37,500 | -- | -- | 28% 133.53K to 171.03K | |
| 04-Apr-24 6:17 PM View: | Winningham Rick E Chief Executive Officer Director | Theravance Biopharma, Inc. (TBPH) | 02-Apr-24 | Grant | 300,000 | -- | -- | 18% 1.65M to 1.95M | |
| 04-Apr-24 6:11 PM View: | Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY | Theravance Biopharma, Inc. (TBPH) | 02-Apr-24 | Grant | 100,000 | -- | -- | 38% 260.68K to 360.68K | |
| 04-Apr-24 6:09 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 02-Apr-24 | Grant | 37,500 | -- | -- | 12% 311.73K to 349.23K | |
| 04-Apr-24 6:15 PM View: | Sawaf Aziz SVP & Chief Financial Officer | Theravance Biopharma, Inc. (TBPH) | 02-Apr-24 | Grant | 100,000 | -- | -- | 42% 238.64K to 338.64K | |
| 19-Mar-24 6:06 PM View: | Winningham Rick E Chief Executive Officer Director | Theravance Biopharma, Inc. (TBPH) | 15-Mar-24 | Gift | 3,900 | -- | -- | < 1% 1.65M to 1.66M | |
| 19-Mar-24 6:06 PM View: | Winningham Rick E Chief Executive Officer Director | Theravance Biopharma, Inc. (TBPH) | 15-Mar-24 | Grant | 2,704 | $8.64 | $23,362.60 | < 1% 1.65M to 1.65M | |
| 19-Mar-24 6:06 PM View: | Winningham Rick E Chief Executive Officer Director | Theravance Biopharma, Inc. (TBPH) | 15-Mar-24 | Gift | 10,900 | -- | -- | (< 1%) 1.66M to 1.65M | |
| 22-Feb-24 8:04 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 22-Feb-24 | Market Sale (Planned) | 1,254 | $8.71 | $10,922.30 | (< 1%) 312.99K to 311.73K | (12%) |
| 22-Feb-24 8:14 PM View: | Winningham Rick E Chief Executive Officer Director | Theravance Biopharma, Inc. (TBPH) | 20-Feb-24 | Payment of Exercise | 37,196 | $8.92 | $331,788.00 | (2%) 1.69M to 1.65M | (9%) |
| 22-Feb-24 8:06 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 20-Feb-24 | Payment of Exercise | 19,294 | $8.92 | $172,102.00 | (6%) 334.21K to 314.92K | (9%) |
| 22-Feb-24 8:11 PM View: | Sawaf Aziz SVP & Chief Financial Officer | Theravance Biopharma, Inc. (TBPH) | 20-Feb-24 | Payment of Exercise | 17,036 | $8.92 | $151,961.00 | (7%) 255.67K to 238.64K | (9%) |
| 22-Feb-24 8:10 PM View: | Miller Aine SVP, Dev & Head of IRE Office | Theravance Biopharma, Inc. (TBPH) | 20-Feb-24 | Payment of Exercise | 11,782 | $8.92 | $105,095.00 | (8%) 145.32K to 133.53K | (9%) |
| 22-Feb-24 8:04 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 20-Feb-24 | Payment of Exercise | 18,219 | $8.92 | $162,513.00 | (6%) 331.21K to 312.99K | (9%) |
| 22-Feb-24 8:08 PM View: | Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY | Theravance Biopharma, Inc. (TBPH) | 20-Feb-24 | Payment of Exercise | 17,595 | $8.92 | $156,947.00 | (6%) 278.28K to 260.68K | (9%) |
| 26-Dec-23 6:09 PM View: | Grant Jeremy T Director | Theravance Biopharma, Inc. (TBPH) | 21-Dec-23 | Grant | 11,768 | -- | -- | 100% 0 to 11.77K | |
| 22-Nov-23 6:07 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 21-Nov-23 | Market Sale (Planned) | 1,378 | $10.29 | $14,179.60 | (< 1%) 332.58K to 331.21K | 5% |
| 22-Nov-23 6:14 PM View: | Sawaf Aziz SVP & Chief Financial Officer | Theravance Biopharma, Inc. (TBPH) | 20-Nov-23 | Payment of Exercise | 6,187 | $10.37 | $64,159.20 | (2%) 261.86K to 255.67K | 6% |
| 22-Nov-23 6:07 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 20-Nov-23 | Payment of Exercise | 7,982 | $10.37 | $82,773.30 | (2%) 340.57K to 332.58K | 6% |
| 22-Nov-23 6:16 PM View: | Winningham Rick E Chief Executive Officer Director | Theravance Biopharma, Inc. (TBPH) | 20-Nov-23 | Payment of Exercise | 15,804 | $10.37 | $163,887.00 | (< 1%) 1.7M to 1.69M | 6% |
| 22-Nov-23 6:11 PM View: | Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY | Theravance Biopharma, Inc. (TBPH) | 20-Nov-23 | Payment of Exercise | 7,363 | $10.37 | $76,354.30 | (3%) 285.64K to 278.28K | 6% |
| 22-Nov-23 6:10 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 20-Nov-23 | Payment of Exercise | 12,630 | $10.37 | $130,973.00 | (4%) 346.84K to 334.21K | 6% |
| 16-Nov-23 6:16 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 14-Nov-23 | Market Sale (Planned) | 2,482 | $10.22 | $25,366.00 | (< 1%) 349.32K to 346.84K | 5% |
| 01-Nov-23 6:35 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 30-Oct-23 | Grant | 15,000 | -- | -- | 4% 334.32K to 349.32K | |
| 18-Oct-23 6:54 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 16-Oct-23 | Market Sale (Planned) | 2,482 | $9.03 | $22,412.50 | (< 1%) 336.8K to 334.32K | (8%) |
| 18-Sep-23 6:08 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 14-Sep-23 | Market Sale (Planned) | 2,482 | $9.89 | $24,547.00 | (< 1%) 339.29K to 336.8K | 2% |
| 24-Aug-23 6:05 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 22-Aug-23 | Market Sale (Planned) | 1,807 | $9.47 | $17,112.30 | (< 1%) 342.37K to 340.57K | (3%) |
| 22-Aug-23 6:19 PM View: | Winningham Rick E Chief Executive Officer Director | Theravance Biopharma, Inc. (TBPH) | 20-Aug-23 | Payment of Exercise | 15,804 | $9.70 | $153,299.00 | (< 1%) 1.72M to 1.7M | (< 1%) |
| 22-Aug-23 6:10 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 20-Aug-23 | Payment of Exercise | 10,460 | $9.70 | $101,462.00 | (3%) 352.83K to 342.37K | (< 1%) |
| 22-Aug-23 6:15 PM View: | Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY | Theravance Biopharma, Inc. (TBPH) | 20-Aug-23 | Payment of Exercise | 8,912 | $9.70 | $86,446.40 | (3%) 294.21K to 285.3K | (< 1%) |
| 22-Aug-23 6:13 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 20-Aug-23 | Payment of Exercise | 10,461 | $9.70 | $101,472.00 | (3%) 349.75K to 339.29K | (< 1%) |
| 22-Aug-23 6:17 PM View: | Sawaf Aziz SVP & Chief Financial Officer | Theravance Biopharma, Inc. (TBPH) | 20-Aug-23 | Payment of Exercise | 7,114 | $9.70 | $69,005.80 | (3%) 268.97K to 261.86K | (< 1%) |
| 15-Aug-23 6:09 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 11-Aug-23 | Market Sale (Planned) | 2,322 | $9.99 | $23,196.80 | (< 1%) 352.07K to 349.75K | 3% |
| 18-Jul-23 6:14 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 14-Jul-23 | Market Sale (Planned) | 2,322 | $9.84 | $22,848.50 | (< 1%) 354.39K to 352.07K | 1% |
| 12-Jun-23 6:08 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 08-Jun-23 | Private Sale (Planned) | 1,790 | $11.13 | $19,922.70 | (< 1%) 354.62K to 352.83K | |
| 23-May-23 7:41 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 20-May-23 | Payment of Exercise | 10,460 | $11.21 | $117,257.00 | (3%) 367.17K to 356.71K | |
| 23-May-23 7:46 PM View: | Sawaf Aziz SVP & Chief Financial Officer | Theravance Biopharma, Inc. (TBPH) | 20-May-23 | Payment of Exercise | 8,744 | $11.21 | $98,020.20 | (3%) 277.72K to 268.97K | |
| 23-May-23 7:48 PM View: | Winningham Rick E Chief Executive Officer Director | Theravance Biopharma, Inc. (TBPH) | 20-May-23 | Payment of Exercise | 15,804 | $11.21 | $177,163.00 | (< 1%) 1.74M to 1.72M | |
| 23-May-23 7:40 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 20-May-23 | Payment of Exercise | 5,567 | $11.21 | $62,406.10 | (2%) 360.19K to 354.62K | |
| 23-May-23 7:44 PM View: | Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY | Theravance Biopharma, Inc. (TBPH) | 20-May-23 | Payment of Exercise | 11,469 | $11.21 | $128,567.00 | (4%) 305.68K to 294.21K | |
| 17-May-23 6:17 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 15-May-23 | Private Sale (Planned) | 2,322 | $11.26 | $26,145.70 | (< 1%) 369.49K to 367.17K | |
| 04-May-23 10:00 PM View: | Gray Susannah Director | Theravance Biopharma, Inc. (TBPH) | 02-May-23 | Grant | 9,132 | -- | -- | 77% 11.82K to 20.95K | |
| 04-May-23 10:00 PM View: | Broshy Eran Director | Theravance Biopharma, Inc. (TBPH) | 02-May-23 | Grant | 9,132 | -- | -- | 15% 60.89K to 70.02K | |
| 04-May-23 10:00 PM View: | Mitchell Dean J Director | Theravance Biopharma, Inc. (TBPH) | 02-May-23 | Grant | 9,132 | -- | -- | 15% 60.89K to 70.02K | |
| 04-May-23 10:00 PM View: | Malkiel Burton G Director | Theravance Biopharma, Inc. (TBPH) | 02-May-23 | Grant | 9,132 | -- | -- | 9% 106.46K to 115.59K | |
| 04-May-23 10:00 PM View: | Smaldone Alsup Laurie Director | Theravance Biopharma, Inc. (TBPH) | 02-May-23 | Grant | 9,132 | -- | -- | 20% 44.66K to 53.79K | |
| 18-Apr-23 5:49 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 14-Apr-23 | Private Sale (Planned) | 2,323 | $11.88 | $27,597.20 | (< 1%) 371.82K to 369.49K | |
| 16-Mar-23 10:00 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 14-Mar-23 | Market Sale (Planned) | 2,323 | $10.32 | $23,973.40 | (< 1%) 374.14K to 371.82K | 6% |
| 13-Mar-23 5:57 PM View: | Farnum Rhonda SVP, Comm & Medical Affairs | Theravance Biopharma, Inc. (TBPH) | 09-Mar-23 | Market Sale | 4,000 | $10.20 | $40,800.00 | (1%) 364.19K to 360.19K | 5% |
| 08-Mar-23 7:34 PM View: | Graham Richard A SVP, RESEARCH & DEVELOPMENT | Theravance Biopharma, Inc. (TBPH) | 06-Mar-23 | Market Sale (Planned) | 2,323 | $10.05 | $23,346.20 | (< 1%) 376.46K to 374.14K | 3% |
